This study evaluates the incidence of monoclonal B-cell lymphocytosis MBL) in patients with chronic hepatitis C and to determine if monoclonal b-cell lymphocytosis is affected by treatment for hepatitis C.
PRIMARY OBJECTIVES: I. To determine the prevalence of MBL in patients with chronic hepatitis C who are to begin therapy with directly acting antiviral (DAA), and compare with clinic controls who are seen in the general medicine clinic at Mayo Clinic. II. To determine the correlation between the specific subtype of MBL (CD5- MBL, atypical CLL-phenotype MBL and CLL-phenotype MBL) relative to the hepatitis C virus (HCV) genotype. III. To assess the proportion of individuals with MBL who have an improvement in the circulating monoclonal B-cell population following therapy with DAA. OUTLINE: This is an observational study. Patients undergo blood sample collection and have medical records reviewed throughout study.
Study Type
OBSERVATIONAL
Enrollment
29
Non-interventional study
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Prevalence of monoclonal B-cell lymphocytosis (MBL)
Blood samples collected in conjunction with routine clinical blood draws will be tested for MBL and compared with post-therapy samples and with control patients (without hepatitis C).
Time frame: Baseline; up to one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.